Vertaling van "from productivity gains have been " (Nederlands → Frans) :

Gross margin improvements from productivity gains have been mostly reinvested to support the Prevacid24HR launch in the US and sales force expansion across all businesses.
Les gains de productivité ayant permis d’améliorer la marge brute ont été en majorité réinvestis dans le lancement de Prevacid24HR aux Etats-Unis et dans l’expansion de la force de vente dans toutes les activités.

Gross profit margin improvements, productivity gains, and income from an OTC US non-core brand divestment have been the growth drivers, partially offset by higher investments in Marketing & Sales to support new product launches and sales force expansions.
Des améliorations de la marge brute, des gains de productivité et le produit de la cession d’une marque non stratégique d’OTC aux Etats-Unis ont été le moteur de la croissance, qui a été en partie freinée par une hausse des investissements dans Marketing et vente pour soutenir le lancement de nouveaux produits et l’extension des forces de vente.

In Europe, where pricing pressures have been most intense, overall growth was 8 %, with volume gains of 12 percentage points demonstrating the quality of the new product portfolio.
En Europe, où la pression sur les prix a été la plus forte, la croissance globale s’est inscrite à 8%, avec des gains en volume de 12 points ce qui démontre la qualité des nouveaux produits.

Sandoz: –20% to USD 200 million Productivity gains and sustained growth in many regions were more than offset by lower contributions from the US, which included one-time charges of USD 34 million for product recalls and related costs as part of an FDA review of a US production site.
Sandoz: –20% à USD 200 millions Des gains de productivité et une croissance soutenue dans plusieurs régions ont été plus que compensés par une diminution des contributions des Etats-Unis, qui inclut notamment de charges non récurrentes d’USD 34 millions engendrées par des rappels volontaires de produits et coûts annexes dans le cadre d’une révision par la FDA d’un site américain de production.

Sandoz: USD 247 million (+0%) The operating margin rose 1.3 percentage points to 13.9% from the 2008 quarter as focused efforts on productivity gains, including reductions in Cost of Goods Sold and total function costs, helped maintain profitability at the prior-year level despite negative currency movements (–12 percentage points) and lower contributions from the US.
Sandoz: USD 247 millions (+0%) La marge opérationnelle a augmenté de 1,3 point de pourcentage à 13,9%, en comparaison du deuxième trimestre 2008. La concentration des efforts sur les gains de productivité, comprenant une réduction du coût des ventes et des frais de fonctionnement totaux, ont aidé à maintenir la profitabilité au niveau de l’exercice précédent en dépit des changes défavorables (–12 points de pourcentage) et d’une baisse des contributions des Etats-Unis.

Cardiovascular strategic products (USD 6.7 billion, +10% lc) advanced on gains from the new medicines Exforge (USD 406 million) and Tekturna/Rasilez (USD 144 million), which together provided over half of the franchise’s incremental growth, while the Group’s flagship product Diovan (USD 5.7 billion, +10% lc) expanded at a steady pace.
Les produits stratégiques de Cardiovasculaire (USD 6,7 milliards, +10% en m. l) ont bénéficié de gains obtenus par les nouveaux médicaments Exforge (USD 406 millions) et Rasilez/Tekturna (USD 144 millions), qui ont réalisé ensemble plus de la moitié du redémarrage progressif de la croissance de ce secteur d’activité, tandis que Diovan (USD 5,7 milliards, +10% en m. l.), le produit phare du Groupe, a progressé à un rythme régulier.

The Resident Assessment Instrument (RAI) 444 is originally developed to Only for breast cancer and colon cancer, the US has higher survival rates assess the care needs of the elderly in institutions, and has later been than Belgium (data shown in documentation sheet in Supplement S1). To extended with instruments for different care settings and subgroups. In be able to distinguish the effect of early screening from the actual care, Belgium a national pilot project (the BelRAI) is ongoing, but is not yet implemented in all care settings: the assessment instruments for home care, relative survival rates should be compared across countries by stage, for long-term care facilities and acute care have already been adapted to information which is not yet available at international level. the Belgian situation (details in Appendix C).
Belgium a national pilot project (the BelRAI) is ongoing, but is not yet be able to distinguish the effect of early screening from the actual care, implemented in all care settings: the assessment instruments for home care, relative survival rates should be compared across countries by stage, for long-term care facilities and acute care have already been adapted to information which is not yet available at international level. the Belgian situation (details in Appendix C).

Gains were also seen in the US (USD 7.1 billion, +10% lc), while Japan (USD 2.2 billion, +9% lc) benefited from new product launches.
Les Etats- Unis (USD 7,1 milliards, +10% en m. l) ont aussi affiché des gains, tandis que le Japon (USD 2,2 milliards, +9% en m. l) a bénéficié du lancement des nouveaux produits.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated. In addition to these 74 indicators, 11 indicators for which data are expected
Another 12 indicators have been removed from the 2010 set, because they were deemed as not being relevant anymore, or because data were outdated.